MHRA Corrects Fosamax Advertising Complaint
This article was originally published in The Pink Sheet Daily
Merck Sharp & Dohme promotional materials do not directly refer to Teva UK Limited's generic alendronic acid, the U.K. agency now says.
You may also be interested in...
UK Merck subsidiary issues corrective statement acknowledging no superiority over Teva’s generic alendronic acid, as required by the British Medicines & Healthcare products Regulatory Agency.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.